MP12-02 RACE REPORTING IN PROSTATE CANCER FOCAL THERAPY CLINICAL TRIALS

Abstract

You have accessJournal of UrologyCME1 Apr 2023MP12-02 RACE REPORTING IN PROSTATE CANCER FOCAL THERAPY CLINICAL TRIALS Dhaval Jivanji, Arshia Sandozi, Katiana Vazquez-Rivera, Karis Buford, Mariela Martinez, David Silver, and Ariel Schulman Dhaval JivanjiDhaval Jivanji More articles by this author , Arshia SandoziArshia Sandozi More articles by this author , Katiana Vazquez-RiveraKatiana Vazquez-Rivera More articles by this author , Karis BufordKaris Buford More articles by this author , Mariela MartinezMariela Martinez More articles by this author , David SilverDavid Silver More articles by this author , and Ariel SchulmanAriel Schulman More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003227.02AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Focal therapy has emerged as a primary treatment for localized prostate cancer, but there is limited evidence about its impact on oncological outcomes. Furthermore, there is a paucity of data looking at focal therapy in diverse racial populations. The objective of this study is to elucidate the current state of representation of non-white men in clinical trials investigating focal therapy. METHODS: PubMed and clinicaltrials.gov were queried using the search terms “prostate cancer” and “focal therapy” to identify all published and completed clinical trials between 2015-2022. Study characteristics were extracted and those that reported race information were further analyzed. Trials were excluded if focal therapy was used in combination with other treatments or used as salvage therapy. RESULTS: In total, 69 clinical trials (63 manuscripts, 6 completed clinical trials) were found to meet our inclusion criteria. HIFU (n=24, 34.8%), brachytherapy (n=9, 8.7%) and cryoablation (n=9, 8.7%) were the top three modalities studied. We found that 12/69 (17.4%) trials provided data on race which enrolled 945 patients. Within these studies, African American men only represented 4.3% of subjects (n=41). White subjects made up the vast majority of participants (n=871, 92.2%) followed by Multiracial subjects (n=18, 1.9%) and Asian subjects (n=8, 0.9%). CONCLUSIONS: Race was reported in only 17.4% of clinical trials studying focal therapy over the past eight years. Of the trials reporting race, African American men constituted <5% of study participants despite having the highest incidence of prostate cancer in the United States. It is incumbent upon future studies to report race data and to establish clinical trial enrollment protocol to address this discordance. Source of Funding: None © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e133 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Dhaval Jivanji More articles by this author Arshia Sandozi More articles by this author Katiana Vazquez-Rivera More articles by this author Karis Buford More articles by this author Mariela Martinez More articles by this author David Silver More articles by this author Ariel Schulman More articles by this author Expand All Advertisement PDF downloadLoading ...